

# Precipio Inc

11:05 29 Apr 2019

## Precipio to provide several hospitals in Cairo, Egypt with diagnostics services

Precipio Inc (NYSE:PRPO), a specialty cancer diagnostics firm, announced Monday it has signed a services contract with several hospitals in Cairo, Egypt that could be worth more than \$1.5 million.

The New Haven, Connecticut-based company did not name the management group nor did it reveal the contract's total amount.

Shares of Precipio jumped 9% to \$5.24 following news of the contract.

**WATCH:** Precipio in talks with international health care systems to expand reach

Precipio said the Cairo hospitals will send patient biopsies for primary diagnosis and secondary consultation. In addition, the contract calls for establishing laboratory operations in Egypt that will license Precipio's proprietary technologies to provide liquid biopsy testing using ICE-COLD PCR technology, and HemeScreen for hematologic molecular testing.

The announcement of Egyptian contract is part of the company's strategy to expand internationally with a focus on Asia, Europe, the Middle East and South America. "The international segment of our business is going to be a valuable contributor to our revenues, margins and cash flow in the coming quarters.," said CEO Ilan Danieli.

The contract also comes as Precipio regained compliance with Nasdaq listing requirements to maintain a minimum bid price of \$1 a share. The company on Friday said it would execute a 1:15 reverse stock split of its common stock, and the post-split took effect Monday, helping to boost the share price.

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @patrickmgraham

**Price:** 2.44

**Market Cap:** \$14.87 m

### 1 Year Share Price Graph



October 2018    April 2019    October 2019

### Share Information

**Code:** PRPO

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>10.8</b>	<b>1.734</b>

**Sector:** Pharma & Biotech

**Website:** [www.precipiodx.com](http://www.precipiodx.com)

### Company Synopsis:

*Precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. Our goal is to assist oncologists in providing the best care for their patients. At the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the Yale School of Medicine.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.